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ABSTRACT 
 
DIB, SHAYMAA, SALAHEDDINE., Masters of Science : January : [2017], Biomedical Sciences 
Title: In-Depth Characterization of Mesenchymal Stem Cells-derived Extracellular Vesicles Using 
Quantitative Proteomics 
Supervisor of Thesis: Dr. Ahmed Malki 
As they home in on injured tissue, modulate the immune system and support 
tissue repairing, mesenchymal stem cells (MSCs) are considered a promising tool for 
many therapeutic applications. In vitro, MSCs have been shown to differentiate into 
multiple cell types mainly of the mesodermal, and more rarely of the endodermal and 
ectodermal lineage under appropriate conditions. In vivo, however, the beneficial effects 
mediated by MSCs are mainly attributed to paracrine factors they provide. MSCs are 
known to secrete large amounts of extracellular vesicles (EVs). EVs are thought to play 
an important role in intercellular communication, transferring proteins, nucleic acids and 
lipids to acceptor cells. To identify factors that contribute to the therapeutics roles of 
MSCs-derived EVs, we characterized the proteins enriched in them. MSCs-derived EVs 
were isolated from conditioned medium of cultured bone marrow–derived MSCs by 
ultra-centrifugation steps differentially isolating microvesicles (MVs) and exosomes. We 
performed LC-MS/MS-based proteomic analysis using reductive dimethylation labeling 
for quantitation of vesicular proteins against MSC whole cell lysate. In total, we 
identified 5207 proteins. 4695 and 4386 proteins were quantified in MVs and exosomes, 
respectively. We further analyzed the up-regulated proteins in both types of vesicles. 
Functional enrichment analysis was performed and hints at a high contribution of both 
MVs and exosomes to therapeutic applications of MSCs. EV proteins were linked to 
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broad biological roles including extracellular matrix organization, cell migration, wound 
healing and hemostasis. Our findings strengthen the idea that MSCs-derived EVs may be 
a valuable replacement for MSCs in therapy. 
 
KEYWORDS: Mesenchymal stem cells, microvesicles, exosomes, quantitative 
proteomics, LC-MS/MS 
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1. INTRODUCTION 
 
 
 
Mesenchymal stem cells (MSCs) are self-renewing multipotent stromal cells 
(Barry & Murphy, 2004), which can be isolated and cultured from several tissues of adult 
or fetal origin with the bone marrow (BM) as the most prominent source (Vallabhaneni et 
al., 2015; Liu & Han, 2008). In vitro, MSCs have been shown to differentiate into 
multiple cell types mainly of the mesodermal lineages, and more rarely of the endodermal 
and ectodermal lineages under appropriate conditions (Jiang et al., 2002). In vivo, 
engraftment of MSCs has been shown to be low and not persistent. MSCs are considered 
a promising tool for many therapeutic applications, as, despite their lack of engraftment, 
they home to injured tissue, modulate the immune system, and support tissue repair. 
MSCs have been shown to have beneficial effects on cardiac function after myocardial 
infarction (Amado et al., 2005), improve lung inflammation and survival (Ortiz et al., 
2007), and repair damaged bone and cartilage (Noël et al., 2002). 
 
MSCs are known to secrete large amounts of extracellular vesicles (EVs), which 
are emerging as important players in intercellular communication and are believed to 
transfer proteins, nucleic acids and lipids to acceptor cells. Microvesicles secreted by 
MSCs may thus have the potential to mimic the therapeutic effects of MSCs. Moreover, 
the vesicles may conceptually be engineered to carry molecules that modulate their 
effects (Tetta et al., 2012). For example, it has been shown that MSC conditioned 
medium has the same effects as MSCs when injected in mice with acute kidney injury (Bi 
et al., 2007) and acute hepatic failure (Parekkadan et al., 2007; Van Poll et al., 2008).  
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1.1. Hypothesis 
This is a screening study to profile proteins in MSCs-derived EVs, and generate 
hypotheses regarding proteinaceous contribution to clinical effects of MSCs in general 
and MSCs-derived EVs specifically. 
 
1.2. Aims 
The aim of this study is the proteomic characterization of MSCs-derived EVs and 
the comparison of these vesicles to their donor cells to gain insight into the proteinaceous 
factors enriched in them. Understanding Pathways, for which members are enriched in 
EVs, may be considered as candidates for EV-modulated pathways, and eventually be 
employed for therapeutic purposes. 
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2. LITERATURE SURVEY 
 
 
2.1. Stem Cells in Cell Therapy 
Stem cells are self-renewing and highly proliferative cells that are able to 
differentiate into specialized mature cells. These characteristics make them an ideal tool 
in cell and gene therapy, drug delivery, and regenerative medicine (Biffi et al., 2013;  
Greco & Rameshwar, 2012;  Law & Chaudhuri, 2013). Despite the intense attention to 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) due to their 
advantages in cell therapy application, major challenges have hindered their progression 
into clinical applications. Ethical issues getting the human oocyte, immune rejection, 
specifically in graft versus host disease, and potential risk of forming teratomas are some 
of ESCs and iPSCs challenges in cell therapy (Kingham & Oreffo, 2013; Abdelalim et 
al., 2014). Unlike ESCs and iPSCs, mesenchymal stem cells (MSCs) overcome these 
major issues. Comparatively, MSCs have no ethical concerns. They have lower risks of 
both immune rejection and teratoma formation (Prockop et al., 2010). 
 
2.2. Mesenchymal Stem Cells 
MSCs are self-renewing multipotent stromal cells that can be isolated and 
cultured from several tissues of adult (e.g. adipose tissue, skin, lung, dental pulp, and 
blood) or fetal (e.g. fetal liver, placenta, and umbilical cord) origin with the bone marrow 
(BM) as the most prominent source (Barry & Murphy, 2004; Liu & Han, 2008; 
Vallabhaneni et al., 2015). MSCs were first isolated from the bone marrow iliac crest of 
guinea pig and cultured by Friedenstein et al. in 1970 (Friedenstein et al., 1970). They 
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were later isolated and cultured from human bone marrow by Haynesworth et al. 
(Haynesworth et al.,1992).,where they represent approximately 0.001–0.01% of the 
nucleated cells present (Pittenger et al., 1999). 
 
According to the minimal defining criteria of the International Society for 
Cellular Therapy: “First, MSCs must be plastic-adherent when maintained in standard 
culture conditions. Second, MSCs must express CD105, CD73 and CD90, and lack 
expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface 
molecules. Third, MSCs must differentiate into osteoblasts, adipocytes and chondroblasts 
in vitro” (Dominici et al., 2006). Moreover, MSCs have the capability to differentiate in 
vitro and in vivo into multiple cell types, mainly to the mesodermal lineages (such as 
adipocytes, osteocytes, chondrocytes, myocytes and cardiomyocytes), and more rarely to 
the endodermal and ectodermal lineages (such as hepatocytes and neurons) under 
appropriate conditions (Jiang et al., 2002).  
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Figure.1: MSCs Isolation, expansion and identification (Konala et al., 2016) 
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2.3. Therapeutic Application of MSCs 
In the recent decade, MSCs are simply isolated and cultured; and their multiple 
characteristics and potency make them attractive and widely chosen for intense 
investigations as a therapeutic tool through both cell-based and cell-free (secretion) 
mechanisms. Currently, more than 646 clinical trials registered within the National 
Institutes of Health are underway evaluating the potential of MSC-based cell therapy 
worldwide (Retrieved from http:// clinicaltrials.gov/, 31 st August 2016). Researchers 
were attracted to MSCs by the context of their ability to home to the injured tissue, 
modulate the immune response, and consequently support tissue repairing.  
 
2.3.1. Role of MSCs in Tissue Regeneration  
Studies and clinical trials of MSC-based therapy indicate the evidence that MSCs 
participate in tissue repair and regeneration. Many studies have been investigating the 
effects of MSCs in improving the function of damaged tissues or organs, such as 
improving cardiac function after myocardial infarction (Amado et al., 2005; Hare et al., 
2009), lung inflammation and survival (Ortiz et al., 2007), and repairing damaged bone, 
cartilage, and skin (Noël et al., 2002; Rasulov et al., 2005).  
 
Several studies have shown that allogeneic or autologous engraftment of MSCs 
improves the treatment process in patients with an acute myocardial infraction. As has 
been reported, that MSCs significantly improve heart function, together with providing 
the clinical safety of the process and providing effectiveness data for further clinical trial 
phases (Hare et al., 2009; Clifford et al., 2012). Fernández García and co-workers 
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strongly demonstrated that co-infusion of MSCs improves and facilitates hematopoietic 
stem cell (HSC) transplantation. Moreover, they claimed that the effect of MSCs is due to 
its direct interaction with HSC which being observed by in vivo and in vitro experiments 
(Fernández-García et al., 2015).  
 
Engraftment of MSCs has been reported to improve bone and cartilage repairing. 
Encouraging results of improving osteoarthritis and meniscal defect appeared in the knee 
joint after MSCs injection (Horie et al., 2009; Davatchi et al., 2011; Agung et al., 2006). 
Horie et al. have shown that MSCs adhered to the injured meniscus after they injected 
them in the defective knee. They directly differentiated into meniscal cells and enhanced 
meniscal regeneration (Horie et al., 2009). Similarly, MSCs improve repairing damaged 
cartilage after differentiated into chondrocytes when injected into a knee joint (Johnson et 
al., 2012; Wakitani et al., 2002).  
 
Many MSC based therapy studies have been conducted as well as for patients 
with neurological disorders, such as stroke and multiple sclerosis (Honmou et al., 2011; 
Karussis et al., 2010; Connick et al., 2011). MSCs are an attractive cellular source for the 
repair of brain disorders, as they express CD90, PDGF-Rb and CD146, which make them 
able to differentiate into dopaminergic neural cells in vitro. They are also able to assist 
endogenous neural growth, protect neuron cells against apoptosis, induce synaptic 
formation, and regulate inflammation (Wolff et al., 2011; Wei et al., 2009). In another 
study, Wolff et al. demonstrated that the engrafted MSCs into the striatum of the 
Parkinson disease mouse model can migrate to the foci of cellular injury in substantia 
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nigra and differentiate there, expressing neuron-like morphology of tyrosine hydroxylase 
positive neuron cells (TH+) and increased levels of dopamine and its metabolite 
production (Wolff et al., 2015).  
Generally speaking, MSCs have the capacity to differentiate and multiply into 
various types of cells, after injection into injured tissues clinically, which enhance tissue 
regeneration.  
 
2.3.2. Role of MSCs in Immunomodulation  
MSCs are able to modulate the innate and adaptive immune system. In the 
adaptive immune system, MSCs impair T-cells maturation and proliferation. For 
example, MSCs cause an increase in IL-10, as well as decreases in interferon-gamma 
(IFN- γ) and tumor necrosis factor-lpha (TNF- α) secretion which alter the 
microenvironment and make changes in immune actions (Aggarwal & Pittenger, 2005; 
Yi & Song, 2012). With regard to the innate immune system, they inhibit monocytes, 
dendritic cells, and natural killer cells maturation and proliferation (Kronsteiner et al., 
2011; Keating, 2012). Moreover, MSCs are characterized by low expression of major 
histocompatibility-II (MHC-II) and other co-stimulatory surface molecules, that make it 
less recognizable by immune cells (Chamberlain et al., 2007). 
 
The connection between the immune system and MSCs has been reported in 
different injury models. In an asthma mouse model, a study showed that BM-derived 
MSCs produce transforming growth factor-b (TGF-b), which suppress allergic responses 
(Nemeth et al., 2010). In a previous study it has been found that both BM-derived MSCs 
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and their vesicles were able to prevent renal fibrosis, lymphocyte infiltrates and tubular 
atrophy in vivo model with kidney injury (He et al., 2012). Moreover, they been used to 
treat graft versus host disease in animal models after bone marrow and HSCs 
transplantation (Kernan et al., 1993). The immunosuppressive properties of MSCs make 
them appropriate cells for allo/autologous transplantation, inflammatory and autoimmune 
disorders (J. Tan et al., 2012). 
 
2.4. MSC Secretomes  
The effects of MSCs on re-modulating different pathological conditions are based 
on their communication with other cells within the microenvironment. Like most cells, 
MSCs communication is characterized by their capability to produce and secrete 
paracrine secretions. These secretions can act as a link between MSCs and the target cells 
to affect on it in different ways and mechanisms. It can regulate the immune response or 
enhance cell proliferation, which both can have a beneficial effect on tissue repairing. 
 
The use of conditioned medium (CM), collected from MSCs culture, is a potential 
alternative for the use of MSCs themselves. Conditioned medium or secretomes of MSCs 
contains secreted biological factors such as proteins, cytokines, chemokines, growth 
factors and other soluble factors or membrane vesicles derived –MSCs (Makridakis et al., 
2013; Collino et al., 2010). Soluble secretions of MSCs and membrane vesicles derived –
MSCs are two recent strategies to improve MSCs-based therapies. They could mimic 
MSCs immunomodulatory regulation and regeneration effects on the hosted cells. 
Moreover, they both could be more practical and decrease risks of MSCs engraftment, 
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which is of central concern in cell therapy (Abreu et al., 2016; Stephen et al., 2016). 
 
The beneficial effects of paracrine factors of MSCs were investigated in many 
studies. MSCs have been shown to be effective in treating various diseases through their 
CM containing all the paracrine factors. In vitro, it has been reported that rat MSCs-CM 
decreased the rate of cardiomyocyte apoptosis after exposure to hypoxia/reoxygenation 
(Xiang et al., 2009). Another study found that MSCs-CM significantly prevent decreasing 
of sodium level in trans-epithelial transport, and preserve epithelial permeability, which 
could help in treating acute lung injury (Goolaerts et al., 2014). In vivo, the paracrine 
protective effect of MSCs has been investigated in induced diabetic rat models. The study 
showed that MSCs secretions can effectively prevent renal injury (Park et al., 2012). 
Other studies have shown that MSCs-CM can mimic the protective effect of MSCs and 
improve tissue repairing when injected in animal models with acute kidney injury (Bi et 
al., 2007), acute hepatic failure (Parekkadan et al., 2007; Van Poll et al., 2008), and 
cornea damage (Roddy et al., 2011).   
          
2.5. Extracellular Vesicles            
Many cells, healthy as well as cancer cells have been shown to secrete 
heterogeneous types of secretion and extracellular vesicles (EVs) into the extracellular 
microenvironment. Vesicles are present in the majority of biofluids, such as serum, urine, 
or cerebro-spinal fluid. EVs have been initially regarded merely as cellular debris without 
biological effects, which discarded the unwanted component of cells. However, many 
recent studies highlighted EVs as a communication system between cells and tissues. 
They carry biological information located in their membrane and cytoplasmic content 
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such as proteins, lipids and genetic material from their parent cells to the target cells, and 
impact thus tissue repairing and immunoregulation. (Camussi et al., 2011; György et al., 
2015; Stephen et al., 2016; Bruno et al.,  2016; Abreu et al., 2016). 
 
  “Extracellular vesicles” is a broad term that is used to refer to the mixture of 
phospholipid membranous vesicles, which can be differentiated based on their sizes and 
intracellular origin. EVs are classified primarily into three main categories: shedding 
microvesicles (MVs), exosomes and, apoptotic bodies. The sizes of membranous vesicles 
are varying in diameter from 50 nm to 2 um. EVs originate from cells by different 
mechanisms, such as direct budding from the plasma membrane in the case of MVs, or 
by fusion of multivesicular bodies (MVBs) that generates exosomes (Houseley et al., 
2006; Théry et al., 2009; György et al., 2015). In addition to size and origin, other 
properties have been used to describe EVs such as density, lipid and protein composition, 
as well as sedimentation rate. Furthermore, factors such as age, gender, physical or 
chemical mediators can affect the nature and number of secreted EVs (Quesenberry et al., 
2014; Abreu et al., 2016).  
                                               
Microvesicles or shedding vesicles are heterogeneous vesicular population 
ranging from 100−1000 nm in diameter. They are circular fragments that bud by direct 
cytoplasmic protrusions, and detach from the cell surface, changing the distribution of 
cell plasma membrane (Muralidharan-Chari et al., 2010; Fierabracci et al., 2015; Stephen 
et al., 2016). The budding process takes place in resting cells. However, the rate of 
shedding formation varies. Factors such as cytosolic calcium ion stimulation, and 
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cytoskeleton reorganization, control the production of shedding vesicles (Cocucci et al., 
2009; Stephen et al., 2016). Phosphatidylserines are highly enriched in MVs, as a result 
of flippase, floppase, and scramblase enzyme activity. For example, increasing level of 
calcium levels cause scramblase activation and accordingly shift phosphatydilserine from 
the inner to the outer membrane lipid bilayer (Camussi et al., 2010; Abreu et al., 2016). 
MVs differ in size and molecular components, according to the origin cell type and the 
process of biogenesis (Camussi et al., 2010). Practically no specific marker has been 
characterized to distinguish MVs. Nevertheless, MVs express some markers of their 
parent cells, and the plasma membrane content reflects the plasma membrane of the 
original cell (Stephen et al., 2016; Bruno et al., 2016).     
          
Exosomes are a smaller type of EVs, which have a more homogeneous shape than 
microvesicles, and ranging from 30−100 nm in diameter. Prior to being release from the 
plasma membrane, exosomes are formed as accumulating intraluminal vesicles inside 
MVBs in the cytoplasm. When a MVB fuses with the plasma membrane, it secretes the 
intraluminal vesicles or exosomes into the extracellular space, in a process called 
exocytosis. Dissimilar to the formation of MVs, exosomes are not depending on calcium 
stimuli (Fierabracci et al., 2015; Sabin & Kikyo, 2014; Camussi et al., 2010; Stephen et 
al., 2016; Abreu et al., 2016; Hall et al., 2016). Most exosomes are highly enriched in 
both Apoptosis Linked Gene -2- Interacting Protein X (Alix) and Tumor Susceptibility 
Gene 101 (Tsg101), which are involved in the biogenesis of MVBs. The tetraspanins 
group containing CD9, CD63 and CD81 are also highly enriched in exosomes and has 
been widely known as exosomal markers. Furthermore, exosomes express many other 
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markers that reflect their parent cells and help in their identification (Bruno et al., 2016; 
Hall et al., 2016; Stephen et al., 2016). 
  
Apoptotic bodies are another type of EVs, ranging from 1000 to 5000 nm in 
diameter. Apoptotic bodies are released from the plasma membrane of dying cells during 
apoptosis. They contain DNA, noncoding RNAs and cell organelles (Fujita et al., 2015; 
Akers et al., 2013). 
 
EVs can affect target cells by different mechanisms/pathways. EVs can modify 
cells through interaction of EVs-surface receptors with the membrane of recipient cells 
(Cocucci et al., 2009). They can also fuse to the target cells, and transfer their biological 
contents such as proteins, RNAs, and lipids, which modify the function of the target cell 
(Mathivanan et al., 2010; Phinney et al., 2015a). The practical effects of the EVs depend 
on the conditions of the cells they were secreted from. For example, EVs can behave as 
immunostimulators or immunosuppressants (Bourdonnay et al., 2015). In this context, 
dendritic cells secrete EVs, which can induce humoral immune responses against 
antigens (Qazi et al., 2010). On the other hand, lipopolysaccharide-activated monocytes 
are able to activate caspase pathway and consequently apoptosis of the target cells 
(Sarkaret al., 2009). 
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Table.1: Summary of characterization of extracellular vesicles 
EVs Microvesicles Exosomes Apoptotic bodies 
Size 100 -1000 nm 30 – 100 nm > 1000 nm 
Genesis Direct budding of the 
plasma membrane 
Exocytosis of multivesicular 
bodies to the plasma 
membrane  
Blebbing of plasma 
membrane during apoptosis 
Contents Proteins, lipids, mRNA, 
micro RNA, rarely DNA, 
and cell organelles  
Proteins, lipids, mRNA, 
micro RNA, rarely DNA 
Fragmented DNA, non 
coding RNA, and cells 
organelles 
 
Markers Tetraspanins (CD63, CD81, 
CD9), Integrin, selectin, 
flotillins, and membrane 
related cell markers 
Tetraspanins (CD63, CD81, 
CD9), heat shock proteins, 
Alix, Tsg101, integrin, and 
annexin 
Phosphatidyl-serine, and 
membrane related cell 
markers 
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Figure.2: Schematic representation of the origin of EVs. MVs originate from direct 
budding of the plasma membrane, exosomes originate from exocytosis of MVBs out of 
the plasma membrane, and apoptotic bodies are as a result of blebbing of plasma 
membrane of the apoptotic cells. (Bruno et al., 2016) 
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2.6. Therapeutic Effects of MSCs-derived EVs 
MSCs beneficial effects have been attributed to their secretion such as soluble 
factors and EVs. MSCs are known to secrete large amounts of EVs, which are emerging 
to have the potential to mimic MSCs in playing an important role in tissue regeneration 
and immunomodulation. They even could be more beneficial than the MSCs themselves 
for their therapeutic advantages. MSCs-derived EVs have been most widely studied in 
recent years. MSCs-derived EVs present surface markers such as CD29, CD44, CD73, 
CD105 and some molecules, which have been originally described as enriched in the 
mesenchymal lineage (Bruno et al., 2009; Amiri, et al., 2015; Abreu et al., 2016). They 
have been shown to be enriched with anti-apoptotic microRNA (miRNAs) and other 
soluble factors that can improve wound healing and angiogenesis (Amiri et al., 2015). 
Moreover, these vesicles may conceptually be engineered to carry molecules that 
modulate their targets (Tetta et al., 2012).  
 
2.6.1. Roles of MSCs-derived EVs in Tissue Regeneration  
The therapeutic effects of MSCs-derived EVs have been examined in various 
disease conditions in in vivo and in vitro models.  
 
The Heart: The therapeutic effects of MSCs-derived EVs in myocardial injury 
models have been studied. It has been demonstrated that injected MSCs-derived EVs 
significantly decrease infarction size and oxidative stress, increase production of ATP 
and NADH, modulate inflammatory activities and activated the pro-survival signaling 
(PI3K/Akt pathway), which leads to enhanced cardiac function and reduced ischemic / 
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reperfusion acute myocardial injury in vivo models (Lai et al., 2010; Arslan et al., 2013; 
Bian et al., 2014). Kang et al. and his colleagues have reported the effect of MSCs-
derived EVs on cardiac functions in vitro and in in vivo myocardial infarction models. 
They revealed that the CXCR-4 which is overexpressed by exosomes is acting to promote 
restoration of heart function and reduce left ventricular remodeling (Kang et al., 2015). 
Genetic information carried by MSCs-derived exosomes such as miRNAs have a cardio-
protective role and saves cardiomyocytes against apoptosis and fibrosis (Feng et al., 
2014). 
 
Kidney and liver: Similar to MSCs treatment effects, several studies suggest that 
MSCs-derived EVs could significantly protect against kidney and liver injury through 
different experimental models. The therapeutic effects of MSCs-derived EVs have been 
investigated in acute kidney injury (AKI) models which were induced by hypoxia, 
ischemia–reperfusion, cisplatin, glycerol, gentamicin, and nephrectomy (Monsel et al., 
2016). Bruno et al. found that MSCs-derived EVs enhancing the recovery of glycerol-
induced AKI in an in vivo model of severe combined immunodeficiency mice. It 
improved the recovery of AKI through preventing apoptosis and increasing renal tubular 
epithelial cell proliferation (Bruno et al., 2009). In another study, these vesicles were 
found to assemble in glomeruli and tubules, give rise to a proliferation of tubular cells 
and consequently protect against both acute and chronic kidney injury development 
(Gatti et al., 2011). In hypoxic injured kidney tissues, MSCs-derived EVs have been 
shown to reduce the oxidative stress and apoptosis that result in improving renal function 
in AKI (G. Zhang et al., 2016).  
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Some other studies have focused on the role of MSCs-derived EVs in treating 
induced liver injury in vivo models (Li et al., 2013; C. Y. Tan et al., 2014). Li et al. 
illustrated that MSCs-derived EVs could mitigate liver fibrosis by decreasing the 
production of collagen, inhibiting TGF-β1/Smad phosphorylation signaling pathway, and 
restoring the function of aspartate aminotransferase (Li et al., 2013). Moreover, Tan et al. 
investigated the therapeutic effect of MSCs-derived EVs in induced liver injury. They 
found that vesicles administration could enhance liver regeneration through increasing 
hepatic cell proliferation, as a result of higher expression of proliferation proteins (PCNA 
and cyclin D1), and anti-apoptosis gene (Bcl-XL) (C. Y. Tan et al., 2014). 
 
Brain: The therapeutic effect of MSCs-derived EVs have been studied in models 
of neurological disorders and shown to mimic the beneficial effects of MSCs. Doeppner 
et al. study demonstrated that BM-MSCs-derived EVs induced neuro-protection, neuro-
regeneration, and improve stroke recovery (Doeppner et al., 2015). MSCs-derived 
exosomes have been shown to enhance the motor function of neuron axons by 
transferring microRNAs, from MSCs and load them into the recipient injured neural cells 
(Xin et al., 2013). Exosomes are non-toxic, have small size and a lipid-bound biogenic 
nature. These characteristics make them fit to cross through the blood brain barrier to 
reach the target cells (Xin et al., 2013; Pusic et al., 2014). In a comparison study between 
the effect of MSCs and their secretome, Lopez-Verrilli et al. observed that neuronal 
growth was inhibited by MSCs, and enhanced by their secretome, especially exosomes 
(Lopez-Verrilli et al., 2016). They supported the idea that MSCs-derived exosomes are 
more associated with beneficial effects and promote regeneration in the central and 
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peripheral nervous system after nerve injury.  
 
Lung: The anti-inflammatory effects of MSCs-derived EVs were demonstrated in 
several in vivo models of acute lung injury (ALI). In Escherichia coli-induced ALI, Zhu 
et al. demonstrated that MSCs-derived EVs reduced inflammation and protein 
permeability in lung, which leads to protection from pulmonary oedema (Zhu et al., 2014; 
Monsel et al., 2015). In silica-induced ALI, Phinney et al. showed that MSCs-derived 
exosomes reduce the nodules size and leukocyte number in bronchial lavage fluid of 
murine lung (Phinney et al., 2015). Similarly, in a mouse model of hypoxia-induced 
pulmonary arterial hypertension, Lee et al. reported that MSCs-derived exosomes 
suppress the early hypoxic signal, and act as anti-inflammatory tool by activating the 
alveolar macrophages (Lee et al., 2012). 
 
Taken together, administration of MSCs-derived EVs can be a powerful 
therapeutic tool to transport the needed molecules to target tissues, which could lead to 
treatment of various disease conditions. 
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2.6.2. MSCs-derived EVs Role in Immunomodulation 
Secreted vesicles mimic the immunoregulatory effects of whole cells. Several 
studies have investigated the various immunomodulatory effects of MSCs-derived EVs in 
different experimental models of immune-related diseases.  
 
The effects of MSCs-derived EVs against adaptive immune cells (T-cell subsets 
and B-cells) have also been shown. For example, in a study by Mokarizadeh, the authors 
showed that BM-MSCs -derived MVs inhibit auto-reactive splenic mononuclear cells 
activation and proliferation by their tolerogenic molecule contents such as PDL-1, TGF-
β, and galecin-1. Furthermore, they showed that when these vesicles are added to splenic 
mononuclear cells, they Inhibit T-cells differentiation and activation, as well as the 
interferon-gamma (IFN-γ) secretion. Also, vesicles induce T-cells to secrete anti-
inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor -β 
(TGF-β), and activate CD4+, CD25+, Foxp3+ regulatory T cell (Treg) generation and 
differentiation (Mokarizadeh et al., 2012). Another study investigated that human adipose 
MSCs-derived exosomes suppress CD4+ and CD8+ T cells activation, proliferation and 
differentiation in vitro, and significantly inhibit their IFN-γ secretion (Blazquez et al., 
2014). In addition, microvesicles derived from MSCs were found to modulate T cell anti-
inflammatory response in vitro model of type-1 diabetes. They have been found to 
increase T-regulatory cells and their regulatory secretions such as PGE2 and TGF-β, and 
decrease of Th1 and Th17 cells along with their cytokine secretions (Favaro et al., 2014).  
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Interestingly, in a study conducted for investigating the effects of vesicles derived 
from MSCs on glioblastoma cells, both vesicles isolated from BM or umbilical cord -
MSCs were found to decrease glioblastoma cell proliferation, while vesicles isolated 
from adipose tissue were found to increase them (Del Fattore et al., 2015). This suggests 
that MSCs-derived EVs can either induce or inhibit the immune responses based the 
tissue of origin, which has to be considered especially in immuno-studies. Researchers 
suggest that MSCs-derived EVs have a wide range of immunomodulatory effects on 
different types of the immune system cells and their ability to modulate diseases, which 
open the way toward new treatment application of autoimmune diseases. 
 
In addition to their effects on adaptive immune system, MSCs-derived EVs may 
also target innate immune cells. A study by Zhang et al. demonstrated that MSCs-derived 
EVs activate M2-like monocytes, which subsequently increase regulatory T cell and 
improve allogeneic skin graft survival in mice (B. Zhang et al., 2014). Another study 
found that, when macrophages engulf the MSCs-derived EVs, the vesicles transfer their 
mitochondrial contents and consequently inhibit Toll-like receptor expression and 
signaling in macrophages. This lead to inhibited macrophage activation and suppresses 
the inflammation in lung injury models (Phinney et al., 2015). In the same way, Favaro et 
al. demonstrated that MSCs-derived EVs could target dendritic cells and inhibit their 
maturation in patients with type-1 diabetes, which delay T cells autoreactive and promote 
the anti-inflammation( Favaro et al., 2016).  
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MSCs-derived EVs have also a strong inhibitory effect on B lymphocytes 
proliferation and differentiation and their immunoglobulin secretion, when they co-
culture with peripheral blood mononuclear cells (Budoni et al., 2013). 
 
2.7. Advantages of MSCs -derived EVs over MSCs 
Despite the promising strategies to overcome MSCs challenges in cell therapy, 
some challenges such as their low proliferation rate, and the restricted life span during in 
vivo and in vitro expansion, hinder their use in cell therapy. For examples, during in vivo 
transplantation, MSCs undergo apoptosis, resulting in as many as 99 % cell death during 
the first few days post transplantation. As a result, only a few MSCs reach the target 
when injected in vivo, while the majority remain accumulating in the lungs, spleen and 
liver (Toma et al., 2002; Boyette & Tuan, 2014). 
 
Such issues may be overcome by cell-free strategies, which have shown beneficial 
effects under many different pathological conditions.  Especially promising agent of such 
therapies are MSCs-derived EVs, which have many therapeutic advantages over the 
MSCs themselves: 1) MSCs-derived EVs may decrease some of MSCs engraftment 
associated risks like MSCs trapping and apoptosis. So, vesicles are able to home to the 
target tissue, without accumulation in other organs. 2) They also have as lower risk of 
tumor generation (Abreu et al., 2016). 3) They have less immune rejection than MSCs 
after injection. This is due to lower cell surface protein content such as major 
histocompatibility complex molecules compared to parental MSCs, which decrease the 
organ persistence (Konala et al., 2016). 4) Unlike secreted soluble factors such as 
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cytokines, growth factors, and RNAs, MSCs-derived EVs are encapsulated, and their 
content is protected from rapid degradation even after long storage for 6 months at -20 C 
(Konala et al., 2016). 
 
2.8. MSCs-derived EVs Isolation Methods 
Different types of EVs can be isolated and purified from biological fluids or from 
conditioned media of cell culture. Numerous isolation protocols can be used to purify 
EVs according to their size, density, biochemical and biophysical properties. The 
purification of EVs is mainly achieved by three methods, namely ultracentrifugation, 
ultrafiltration and immunoprecipitation using antibody-loaded magnetic cell beads 
(Maumus et al., 2013). 
 
The most commonly accepted and used method to isolate EVs is differential ultra-
centrifugation. It is a series of repeating centrifugation steps involving gradually 
increasing speeds, which isolates vesicles according to their size and density. First a low-
speed centrifugation removes cells, large apoptotic bodies and other debris, followed by 
10,000–20,000 ×g centrifugation to pellet microvesicles (MVs), and finally ultra-
centrifugation (100,000–120,000 ×g) to pellet exosomes. After each centrifugation, the 
supernatant is collected and transferred to another tube, while the pellet is kept. Although 
ultra-centrifugation is the most commonly used and considered the gold-standard method 
to isolate EVs, it has certain challenges and limits, which doesn’t make it proper method 
under all conditions. Some of these limits are the length of centrifugation time, the 
amount of contaminants that may be pelleted with centrifugation, and non-strict vesicle 
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separation due to overlapping size spectra (Théry et al., 2002; Théry et al., 2006; Witwer 
et al., 2013; Peterson et al., 2015; Rani & Ritter, 2016). EVs can be purified based on 
their different density by floatation the sample containing EVs into a sucrose density 
gradient/ sucrosedeuterium oxide (D2O) cushions under centrifugation. This protocol is 
helping to avoid protein co-pelleting with EVs (Théry et al., 2002; Théry et al., 2006).  
 
In addition, ultrafiltration is another commonly used isolation protocol that can be 
used to eliminate various contaminations based on their hydrodynamic radii. It can be 
used alone or with other isolation procedures such as ultra-centrifugation or size 
exclusion chromatography. In ultrafiltration protocol, sample contained vesicles are 
filtered through a semipermeable membrane. Although this technique has some 
disadvantages such as blocking of filters and shearing stress that may affect the vesicles 
characteristics, it has been reported that vesicles yield is more as compared to 
ultracentrifugation-based isolation (Théry et al., 2006; Nordin et al., 2015; Rani & Ritter, 
2016). 
 
Size exclusion chromatography has also been used to isolate vesicles. 
Chromatography separation is most often used after low speed centrifugation to eliminate 
the large contaminants and filtration to concentrate the sample. Based on their variety of 
vesicles size, they can pass through the stationary phase of a chromatography column 
differentially and are thus separated (Böing et al., 2014; Muller et al., 2014).  
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Additionally, vesicles can be extracted based on their membranous protein 
expression. Immunoaffinity purification is a technique that uses micro-beads coated with 
specific antibodies against proteins on the vesicle surface. So that vesicles can be sorted 
out by choosing the correct antibodies for the wanted vesicles. This technique has also 
been used as an additional isolation step after ultracentrifugation or filtration. The limit of 
this method is that only vesicles that have the selected protein can be isolated, while the 
rest of vesicles in the sample are neglected (Théry et al., 2002; Théry et al., 2006; Tauro 
et al., 2012). 
 
In fact, there is no one best method to isolate vesicles. The choice of isolation 
method differs between laboratories and many factors affect it. Just to mention some: 
purity and origin of the samples containing vesicles, type of vesicles intended to be 
isolated, follow-up measurements. Before designing any isolation experiment, such 
factors must be taken in consideration, and characteristics of isolated vesicles must be 
precisely analyzed (Cvjetkovic et al., 2014). 
 
2.9. MSCs-derived EVs proteome 
Proteomics techniques such as mass spectrometry (MS) and protein microarrays 
have been emerging as an effective tool to characterize the protein of any complex 
mixture. Mass spectrometry, the most common proteomics technique, has increased our 
understanding of the protein complexes and their related biological questions. This 
technology allows peptide sequencing, which enable peptides and proteins quantification 
and identification (Han et al., 2008; Mallick & Kuster, 2010). 
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Quantitative proteomic strategies such as stable isotope dimethyl labeling, and 
stable isotope labeling with amino acids in cell culture (SILAC) are currently being 
widely applied. The idea behind stable isotope labeling is creating a mass shift between 
identical peptides, in order to distinguish and compare the relative abundances of the 
same protein in different conditions in one MS analysis. Differential protein expression 
profiling allows signaling pathway analysis, which helps developing protein biomarkers 
(Han et al., 2008; Kovanich et al., 2012). 
 
In the past few years, proteomic analyses have contributed significantly to clarify 
the molecular composition of extracellular vesicles and identified proteins that might be 
associated with fundamental functions and pathways. Few comprehensive mass 
spectrometry-based proteomic studies of MSCs-derived EVs have been performed (Kim 
et al., 2012; Lai et al., 2012; Eirin et al., 2016). These previous studies profiled the 
proteome of MSCs-derived EVs using LC-MS/MS proteomic analyses to understand 
their potential therapeutic effects. Identified proteins were classified over different 
biological process groups including vesicles structure, biogenesis, self-renewing, 
differentiation, proliferation, communication, and tissue repair related proteins that can 
be associated with the therapeutic effects of MSCs-derived EVs. These proteomic 
profiling give understanding to their impact on tissues recovery in order to identify 
candidate proteins associated with their therapeutic potential in various pathological 
conditions.   
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3. MATERIALS 
 
 
 
3.1. Materials Used for Bone Marrow Mesenchymal Stem Cell Culture 
 Tissue Culture Catalog 
Number 
Company Country 
1 Counting Slides, Dual Chamber For Cell 
Counter 
145-0011 Bio-Rad USA 
2 Dulbecco’s Phosphate Buffered Saline 
(DPBS) 
55-031-PB Corning USA 
3 Eppendorf Centrifuge 5804 Eppendorf 
AG 
Germany 
4 Human Mesenchymal Stem Cells PT-2501 Lonza USA 
5 L-Glutamine,100x 
 
25-005-CI Corning USA 
6 Mesencult TM MSC Basal Medium (Human)  
Mesenchymal stem cell stimulatory 
supplements (Human) 
05401 
 
05402 
Stem Cell 
Technology 
Canada 
7 Penicillin/streptomycin solution,100 x 30-002-CI Corning USA 
8 TC20 Automated Cell Counter 508BR04557 Bio-Rad USA 
9 Tissue Culture Flask, 75 cm2 353136 Falcon USA 
10 Trypan Blue Dye, 0.40% 145-0013 Bio-Rad USA 
11 Trypsin EDTA,1 X 25-052-CI Corning USA 
 
3.2. Materials Used for Extracellular Vesicles Harvesting 
 Extracellular Vesicles Harvesting Catalog 
Number 
Company Country 
1 100 Ti Rotor, Fixed Angle 363013 Beckman 
Coulter 
USA 
2 Avanti J-30I Centrifuge J-301 Beckman 
Coulter 
USA 
3 JA-20 Rotor, Fixed Angle 334831 Beckman 
Coulter 
USA 
4 Optima™ L-100 XP Ultracentrifuge  392050 Beckman 
Coulter 
USA 
5 Polyallomer bottles 50 ml 357003 Beckman 
Coulter 
USA 
6 Polycarbonate Thick Wall Centrifuge Tubes 355645 Beckman 
Coulter 
USA 
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3.3. Materials Used for Extracellular Vesicles Protein Extraction 
 
 3.4. Materials Used for Protein Gel 
 
 
 
 Protein Extraction Catalog 
Number 
Company Country 
1 96-Well ELISA Plate 353072 Falcon USA 
2 Albumin Standard Ampules 23209 Thermo 
Scientific 
- 
3 Benzonase Nuclease  E1014 Sigma Denmark 
4 Chloroform Anhydrons 372978 Sigma USA 
5 CLARIOstar Microplate Reader  - BMG LabTech - 
6 HPLC-Grade Methanol 34860 Sigma USA 
7 HPLC-Grade Water 34877 Sigma USA 
8 Phosphatase Inhibitors PhosStop 04906837001 Roche Germany 
9 Protease Inhibitors Complete EDTA-
Free 
11873580001 Roche Germany 
10 Quick Start Bradford 1x Dye 
Reagent 
500-0205 Bio-Rad USA 
11 Sodium Dodecyl Sulfate Solution 05030 Sigma Switzerland 
12 Urea U5128 Sigma Germany 
 Protein Gel Catalog 
Number 
Company Country 
1 Dl-Dithiothreitol  D0632 Sigma  
2 MES SDS Running Buffer 
 
786-531 G-biosciences USA 
3 NuPAGE® LDS Sample Buffer (4X) NP0007 ThermoFisher 
scientific 
USA 
4 NuPAGE™ Novex™ 4-12% Bis-Tris Protein 
Gels, 1.0 mm, 15-well 
NP0323 
 
Invetrogen Carlsbad 
5 PageRuler™ Plus Prestained Protein 
Ladder 
26619 ThermoFisher 
scientific 
Lithuania 
6 Quick Start™ Bradford 1x Dye Reagent  5000205 Bio-rad USA 
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3.5. Materials Used for In Solution Digest 
 
3.6. Materials Used for Reductive Dimethyl Labeling for Peptides 
 Reductive Dimethyl Labeling Catalog 
Number 
Company Country 
1 Ammonia Solution (25%) 105428 Millipore 
Chemicals 
Germany 
2 Deuterium oxide (D2O; heavy water; 99.98 
atom% ± 0.01 atom% D 
364312 Sigma - 
3 Formaldehyde (CH2O) Solution (37%) 252549 Sigma Netherlands 
4 Formaldehyde-13C-D2 (13CD2O) Solution (20 
Wt. % In D2O, 98 Atom %D, 99 Atom % 13C) 
596388 Sigma USA 
5 Formaldehyde-D2 (CD2O) Solution (~20 Wt. 
% In D2O, 98 Atom % D) 
492620 Sigma USA 
6 Formic Acid (98%) FX0440-7 Millipore 
Chemicals 
- 
7 HPLC-grade light water (CHROMASOLV Plus 
for HPLC 
34877 Sigma USA 
8 Sodium Cyanoborodeutride (NaBD3CN) Sc-258163 Santa Cruz - 
9 Sodium Cyanoborohydride (NaBH3CN) 156159 Sigma USA 
 
 
 
 In Solution Digest Catalog 
Number 
Company Country 
1 Dl-Dithiothreitol (DTT) D0632 Sigma USA 
2 Iodoacetamide (IAA) I1149 Sigma USA 
3 Lysyl Endopeptidase-Sequencing Grade 
From Lysobacter Enzymogenes 
129-02541 Wako 
Chemicals 
- 
4 Sequencing Grade Modified Trypsin V511a Promega - 
5 Triethylammonium Bicarbonate Buffer 
(TEAB) 
T7408 Sigma Switzerland 
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3.7. Materials Used for Isoelectric Focusing 
 Isoelectric Focusing 
 
Catalog 
Number 
Company Country 
1 OFFGEL low resolution kit 5061-0202 Agilent 
Technologies 
Germany 
2 G3100 OFFGEL fractionator DE01500760 Agilent 
Technologies 
Germany 
3 Immobiline TM Dry Strips, pH 3-11, NL, 13 
cm 
17-6003-75 GE Healthcare Sweden 
4 IPG buffer, pH 3-11 NL 17-6004-40 GE Healthcare Sweden 
 
3.8. Materials Used for STAGE Tipping  
 Stage Tipping and Elution Catalog 
Number 
Company Country 
1 Acetic Acid 33209 Sigma Germany 
2 Acetonitrile  34967 Fluka Germany 
3 Empore Solid Phase Extraction Disks, C18 
(Octadecyl) 
2215 Empore USA 
4 EpT.I.P.S Reloads 2-200 µl 0030 073.428 Eppendorf Germany 
5 Metal Hub Needle, 17 G, Point Style 3 - - - 
6 Syringe + Needle Part - - - 
7 Trifluoroacetic Acid T6508 Sigma USA 
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4. METHODS 
 
 
 
4.1 Bone Marrow Mesenchymal Stem Cell Culture  
Three different lots of bone marrow-derived mesenchymal stem cells (BM-
derived MSC) from three different human donors were purchased (Lonza). Cryovials of 
BM-derived MSC were quickly thawed not longer than two minutes in a 37 C° water 
bath. Thawed cells were cultured and grown in Mesencult TM MSC Basal Medium 
(complete medium kit with stimulatory supplements) with 1x of penicillin/streptomycin 
solution (100x), and 1x of L-Glutamine (100x). During tissues culturing, cells were 
incubated at 37 C° and 5% CO2 in a humidified incubator. Cells were seeded every 7 
days at 80-90% confluence, while media was changed twice a week. For seeding, cells 
were washed twice with 1X Dulbecco’s Phosphate Buffered Saline (PBS), then detached 
using 1X Trypsin EDTA. Cell count and viability were evaluated using Trypan blue dye 
(50% v/v dilution) and automated cell counting.  According to the recommended seeding 
density provided by the company, cells were plated at 5,000 cells/cm2 (approximately 
375,000 cells / 75 cm2 flasks). Cells used for harvesting of extracellular vesicles (EVs) 
were between passages 4-8. 
 
4.2. Extracellular Vesicle Harvesting 
One week before harvesting EVs, cells were washed twice with 1X PBS; the 
media with centrifuged mesenchymal stem cell stimulatory supplements were added. The 
stimulatory supplement was centrifuged at speed 100,000 g for 4 hours at 4 Co. This is to 
reduce the possible exosomes and proteins that could be contained in the stimulatory 
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supplements and interfere with EVs protein. At 80-90% confluence, conditioned medium 
containing the microvesicles and exosomes secreted from BM–derived MSCs were 
collected. First of all, the conditioned media was centrifuged at 1,200 g speed for 5 
minutes to clean it from dead cells and large debris. The pellet was discarded and the 
supernatant was centrifuged at 5,000 g speed for 10 minutes to discard large proteins. The 
pellet was discarded and the supernatant centrifuged to concentrate the EVs. To harvest 
the large-size vesicles (microvesicles), the supernatant of conditioned medium was 
centrifuged at 20,000 g speed at 4 C° for 1 hour. Supernatant was pipetted out for further 
ultra-centrifugation to pellet the small-size vesicles (exosomes), leaving the pellet of 
microvesicles. The pellet of microvesicles was washed with 1 X PBS buffer and 
centrifuged at the same centrifugation conditions. The supernatant (containing exosomes) 
was further centrifuged using the ultra-centrifuge at 100,000 g speed at 4 C° for 1 hour to 
harvest the exosomes. The pellet of exosomes was washed with 1 X PBS buffer and 
centrifuged at the same centrifugation conditions.  
 
4.3. Extracellular Vesicles Protein Extraction 
Pellets of microvesicles and exosomes were lysed and protein was extracted 
directly using 10 % Sodium Dodecyl Sulfate buffer (SDS). SDS buffer was supplemented 
with protease inhibitors, phosphatase inhibitors and benzonase nuclease. Before storing 
the vesicles lysates in – 80 Co freezer for later use, they were incubated at room 
temperature for 30 minutes for efficient lysis.  
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According to Wessel/Fluegge (Wessel & Flügge, 1984), protein was precipitated 
using methanol/chloroform precipitation method. Precipitation was performed as the 
following: 4 sample volumes of methanol were added to the samples, followed by 1 
sample volumes of chloroform, then 3 sample volumes of dH2O. The sample was 
centrifuged for 10 minutes at 20,000 g speed. After discarding the top aqueous phase, 4 
sample volumes of methanol were added. The sample was centrifuged again for 10 
minutes at 20,000 g speed. Methanol was removed, and precipitated protein was dried.  
Protein pellet was resuspended in 6 M Urea/2 M Thiourea in 10 mM HEPES buffer, pH 
8.0. 
 
Total protein concentration was determined by Bradford assay. Bovine serum 
albumin was used for the standard curve at 0.5, 1, 1.5, 2, 2,5 and 3 ug/µl. Protein 
concentration was read using the CLARIOstar Microplate Reader at 580 nm. 
 
4.4. Protein Gel Electrophoresis 
The MSCs total extract, microvesicles, and exosomes proteins were separated by 
protein gel electrophoresis. Prior to running the gel, proteins were mixed with 100 mM 
dithiothreitol (DTT) and 1X LDS, and then incubated at 95 Co for 5 minutes. 5 µg of 
page ruler marker were loaded as a molecular weight ladder, and a total of 3 µg of total 
cells and vesicles lysate were loaded each lane. The gel was run in MES buffer under the 
following conditions: 200 volt, 125 mA, and 45 minutes. The gel was washed for 10 
minutes 3 times with water before staining overnight. 
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4.5. In Solution Digest 
After 30 minutes reduction with 1 mM of dithiothreitol (DTT) and 20 minutes 
alkylation with 5 mM iodoacetamide in the dark, proteins were digested by Lys-C while 
incubated for 3 hours at room temperature. For efficient trypsin digestion, sample 
containing 6 M of Urea/ 2 M Thiourea buffer was diluted to 2 M Urea using 50 mM 
Triethylammonium Bicarbonate Buffer (TEAB). Proteins were digested by trypsin 
overnight at room temperature. Lys-C and Trypsin were used at enzyme to protein ratio 
of 1:50. The samples were kept in – 80 Co freezer until further use. In solution digest 
protocol is based on (Graumann et al., 2008) 
 
4.6. Reductive Dimethyl Labeling for Peptides 
After protein digestion, stable isotope dimethyl labeling was performed at the 
peptide level. Exosome peptides were labeled as “heavy”, microvesicles as “medium”, 
and total extract of MSCs as “light”. Light, medium, and heavy forms of formaldehyde 
(4% CH2O in H2O, 4% CD2O in D2O, 4% 
13CD2O in D2O) were added to exosomes, 
microvesicles, and MSCs peptides, respectively.  Followed by sodium cyanoborohydride 
(0.6 M of NaBH3CN in H2O), which were added to the samples to be light and 
intermediate labeled, and sodium cyanoborodeuteride (0.6 M of NaBD3CN in D2O), 
which were added to the samples to be heavy labeled. After incubation at 22 Co for 1 
hour while mixing, labeling reactions were quenched by adding 1% of ammonia 
solution, followed by 5% of formic acid to quench the reaction further. The three 
differently labeled samples (total MSC extract as light, MVs as medium, exosomes as 
heavy) were mixed at ratio 1:1:1. The reductive Dimethyl Labeling protocol is based on 
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(Boersema et al., 2009). 
 
Desalting of labeled peptides was performed using Oligo R2 and R3.  R2 and R3 
column was prepared using C18 plug by adding around 1 cm of mixed R2 and R3 slurry. 
Briefly, R2 and R3 beads were conditioned using 100 ul of 0.1 % of trifluoroacetic acid 
(TFA). After which, the peptides are loaded, the beads are again washed with 100 ul of 
0.1 % TFA, then the peptides were eluted using B 60 buffer (60 % acetonitrile, 0.5% 
TFA). Eluted peptides were dried by vacuum centrifugation prior to fractionation by 
isoelectric focusing. 
 
4.7. Isoelectric Focusing 
Peptide mixes were separated into 12 fractions over a pH range of 3-11 by 
isoelectric focusing (OFFGEL fractionator, Agilent) according to manufacturer’s 
protocol with some adaptation. In the running buffer, glycerol was reduced from 6 % to 
0.3%, and the ampholytes were reduced from 1% to 0.1%. After the run, fractions were 
harvested with 1% acetonitrile/0.05% TFA and dried down using a 
vacuumcentrifugation. Until STAGE tipping, peptide fractions were stored at −80 C°. 
 
4.8. STAGE Tipping  
200 µl eppendorf pipettes tips were packed with 3 layers of C18 disks to make the 
STAGETips, which were activated with one methanol wash followed by two washes of 
2% acetonitrile/ 0.1% TFA. After peptides were loaded, STAGETips were washed with 
0.5% acetic acid, and kept in 4 Co until peptide elution. Prior elution, STAGETips were 
  
 
36
washed with 0.5 % acetic acid, followed by 2% acetonitrile/0.1% TFA as an additional 
wash to reduce the ampholytes contamination from IPG buffer. Peptides were eluted 
twice with 200 µl of 60% acetonitrile/0.5% TFA, and then dried down using a 
vacuumcentrifugation. After that, peptides were re-suspended in 0.5% acetic acid to be 
run in LC-MS/MS. 
 
4.9. Mass Spectrometry  
Each experiment, consisting of a heavy, medium and light mixed labeled 
conditions was individually submitted to nano liquid chromatography (LC) coupled to 
mass spectrometry (MS) analysis (Nano LC-MS/MS). The analytical platform consisting 
of an EASY nLC-II system interfaced to a Q Exactive mass spectrometer MS (Thermo 
Scientific, Bremen, Germany). Chromatography conditions were defined as follows: H2O 
with 0.5% acetic acid for mobile phase A; H2O: acetonitrile, 20:80 volume ratio, with 
0.5% acetic acid for mobile phase B; flow-rate of 250 nL/min; injection volume of 6.0 uL 
and a maximal loading pressure of 280 bars. LC separation was done on 20 cm long in-
house packed emitter columns (ReproSil-Pur 120 C18-AQ 3 μm diameter beads, Dr. 
Maisch GmbH) using a gradient ranging from 5 to 30% mobile phase B over 90 min, 
followed by a 25 min wash and column re-equilibration cycle. Precursor scans (MS1 
level) were acquired at a resolution of 70000 (at m/z 300) and an AGC (advanced gain 
control) target value of 3·106 charges (maximum ion injection time 20 ms). 
Fragmentation spectra (MS2 level) were acquired at a resolution of 17500 (at m/z 300) 
and an AGC target value of 1·105 charges (maximum ion injection time 120 ms).  
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4.10. Data Analysis 
Our 36 mass spectrometer runs were analyzed by MaxQuant version 1.5.2.8 using 
a Homo sapiens database downloaded from UniProtKB. MaxQuant is a software package 
used to analyze raw MS data to identify and quantify peptides and aggregate 
corresponding results at the protein level (Cox & Mann, 2008). It can be freely 
downloaded from their site (http://www.maxquant.org). 
 
Proteomic data sets were analyzed using the empirical Bayes moderated T test 
implemented by the limma package <CITE LIMMA> in an in house R analysis pipeline. 
P values were corrected for multiple hypotheses testing using the Benjamini- Hochberg 
correction with an adjusted P value cutoff of 5% (P <0.05). Protein quantification was 
based on two ratio counts. Differential expression analysis was calculated based on log2 
normalized ratios. Protein with adjusted P value < 0.05 and an absolute fold change 
(MVs/TE) or (EXO/TE) > 2 were classified as enriched protein in vesicles, while in case 
(MVs/TE) or (EXO/TE) < -2 were considered as depleted in vesicles. Gene set 
enrichment analyses were performed for vesicle enriched proteins using Fisher’s exact 
test with the total dataset as background. All functionalities for data analysis downstream 
of MaxQuant (normalization, PCA, statistics, gene set enrichments based on GO and 
KEGG) are combined in an in-house-built R package (autonomics).  
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Figure 3: Summary of work plan (prepared using power point document) 
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5. RESULTS 
 
 
 
5.1. Cell Line Culture: BM-derived MSCs 
Light microscopic images of BM-derived MSCs from the three different donors 
are shown in figure.4. BM-derived MSCs appear as fibroblast-like cells with elongated 
spindle shape. MSCs-derived EVs have been obtained from BM-derived MSCs from 
three donors. Both microvesicles and exosomes have been harvested at 70-90% sub-
confluence monolayer at passages 4 to 8. 
 
 
BM-MSC-A                       BM-MSC-B                           BM-MSC-C 
 
 
 
 
 
 
 
Figure.4:  Morphological appearance of BM–derived MSCs while grown in Mesencult
media. Light microscopy (Magnification 4 X), scale bar represents 1000 μm. 
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5.2. Proteins Bands of MSCs Total Extract, Microvesicles and Exosomes 
Figure.5 shows the SDS-PAGE gel of MSCs total extract (TE), and their 
corresponding microvesicles (MVs) and exosomes (EXO) lysates. It shows similar 
pattern of protein bands for each lysate, supporting reproducibility of the vesicle 
preparation and samples processing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.5: SDS-PAGE (4-12 % gradient gel) of MSCs total lysate (TE), their corresponding
microvesicles (MVs) and exosomes (EXO) lysates (in triplicate). 
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5.3. Principal Component Analysis of the 3 Subgroups 
Principal component analysis was applied to provide an overview of the 
separation pattern and the relationship among the three subgroups EXO_MV, 
EXO_MSC, and MV_MSC (Figure.6). PCA in a 2-dimensional graph scatterplot shows 
a clear clustering of the subgroups and validates the experimental design. The second 
component (X2: 16 %) characterizes the proteomes of MVs and exosomes to be much 
closer related to each other as compared to MSC whole cell lysate. 
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Figure.6:  Principal component analysis scatterplot of the 3 comparisons: EXO_MV (Red), 
EXO_MSC (Green), MV_MSC (Blue). 
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5.4. Proteins Enriched in MVs and Exosomes 
A total of 5207 proteins were identified. Out of 4695 proteins quantified in MVs, 
and by applying a fold change cutoff value of 2: 477 proteins were enriched in MVs over 
total extract, 1852 proteins were depleted, and 2366 proteins were equally expressed in 
both MVs and their parent cells (MSCs) (Figure.7). While in the EXO_MSC subgroup, 
4386 proteins were quantified. Out of those, 555 proteins were enriched in exosomes, 
1807 proteins were depleted, and 2027 proteins were equally expressed when compared 
to MSCs (Figure.7). 
 
 
 
 
 
 
 
 
 
Exosomes (4386) MVs (4695)  
Enriched, 
555
Equally 
expressed, 
2027
Depleted, 
1807
Enriched, 
477
Equally 
expressed, 
2366
Depleted, 
1852
Figure.7: Number of differentially expressed proteins in MVs and exosomes compared to 
MSCs proteins based on 2 cutoff fold changes. 
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The majority of proteins identified in the triplicate experiment (4986 out of 5207 
proteins) were quantified in all preparations (MSCs, MVs and EXO). Eighty-nine 
proteins were identified in MSCs total lysate only, while 10 and 11 proteins were 
identified in MVs and exosomes only, respectively (Figure.8). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.8:  Venn diagram of the proteins identified in MSCs, microvesicles (MVs) and 
exosomes (EXO). The majority of proteins identified were common to all preparations. 
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5.5. Analysis of the Most Significantly up-regulated Proteins in Microvesicles and 
Exosomes Compared to MSCs 
The top 36 significantly up-regulated proteins in microvesicles compared to 
MSCs in MV_MSC subgroup are represented in log2 fold changes as triplicate in 
figures.9 and 10. While figures.11 and 12 show the top 36 significantly up-regulated 
proteins in exosomes compared to MSCs in EXO_MSC subgroup. Comparing between 
the top most significant proteins in subgroup MV_MSC with subgroup EXO_MSC, we 
can find that all proteins that up-regulated in MVs are also up regulated in exosomes 
when compared to MSCs (Figure.9). Only a small number of proteins (e. g. PXDN, 
COL6A3, PTX3, LTBP2, and APOB) of the top 36 most significantly up-regulated 
proteins in exosomes were significantly enriched in exosomes and less so in MVs. Table. 
2 shows the significance values, fold changes increase compared to MSCs, and functions 
of these proteins.  
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Figure.9: Bar plot of the most 36 significantly up-regulated proteins in MVs compared 
to MSCs (MV_MSC, Blue), represented in log2 fold changes (in triplicate).  
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Figure.10: Distribution of the most 36 significantly up-regulated proteins in MVs 
compared to MSCs (MV_MSC, Blue), represented in log2 fold changes (in triplicate). 
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Figure.11: Bar plot of the most 36 significantly up-regulated proteins in exosomes 
compared to MSCs (EXO_MSC, green), represented in log2 fold changes (in triplicate). 
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Figure.12: distribution of the most 36 significantly up-regulated proteins in exosomes compared to 
MSCs (EXO_MSC, green), represented in log2 fold changes (in triplicate). 
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Table.2: list of selected proteins that are significantly enriched in exosomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exosomes  MVs Function 
PXDN P = 6.85 –E8  
Fold change = 19   
 
P = 0.00012275 
Fold change = 1.039  
 
• Extracellular matrix 
formation 
(Péterfi et al., 2009) 
 
COL6A3 P = 4.28 –E8 
Fold changes = 14 
 
P = 0.00015434 
Fold change = 0.9 • Extracellular matrix 
organization 
• Cell adhesion 
 
PTX3 P = 1.11-E8 
Fold change = 144 
 
P = 2.45 –E6 
Fold change = 2.5 • Inflammatory 
response, 
• Innate resistance  
 
LTBP2 P = 9.38 –E8 
Fold change = 27 
 
P = 1.38 –E6 
Fold change = 3 
• Extracellular 
organization 
APOB P = 1.37 –E8 
Fold change = 201 
 
P = 4.27 –E8 
Fold change = 24 • Cholesterol and 
Lipid metabolism 
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FBP1,2 protein was the most significant protein in microvesicles (p= 3.09 E-9), 
followed by GPX3 (p= 4.47 E-9), and NBEAL2 (p= 5.2 E-9). The top 20 most significant 
MVs and exosome proteins were sorted by the mean of – log p values and plotted as fold 
changes in figures.13 and 14. Some proteins appear as strong candidates, as they 
significantly detected and highly expressed in vesicles. To mention some, MFGE8 (264 
fold in MVs), and SERPINC1 (196 fold in MVs, 830 fold in exosomes) are significant 
proteins detected in vesicles, which are also significantly up regulated compared to donor 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.13: Bar plot of the top 20 significant MV proteins sorted by the mean of –log p 
values and represented by fold changes.   
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Figure.14: Bar plot of the top 20 significant exosome proteins sorted by the mean of –
log p values and represented by fold changes.   
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As mentioned above, some proteins were differentially detected at significant 
expression levels in MVs and exosomes compared to MSCs. Fold changes of the top 20 
most differentially up-regulated proteins are graphically plotted in figure.15 (for 
microvesicles) and in figure.16 (for exosomes). 
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Figure.15: Bar plot of the top 20 proteins of MVs sorted based on fold changes.   
  
 
53
 
 
0 200 400 600 800 1000 1200 1400
PLEK
FHOD1
HBA2;HBA1
HSPG2
APOB
LRP8
PLTP
FN1
HTRA1
HP;HPR
PRSS23
MFGE8
RBP4
VCAN
SULT1C2
ART4
LAMA4
FERMT3
SERPINC1
APOM
Fold Changes
Figure.16: Bar plot of the top 20 proteins of exosomes sorted based on fold changes. 
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5.6. Gene Ontology Analysis 
Gene ontology (GO) enrichment analyses (including biological processes 
(GOBP), cellular compartments (GOCC), and KEGG pathway) were performed on up-
regulated proteins of MVs and exosomes. The top 20 GO enrichment terms are shown in 
figures.17- 21. Top GOBP terms enriched in MSCs-derived vesicles (microvesicles and 
exosomes) include extracellular organization, cells motion and adhesion, wound healing, 
and others (Figure.17). Common cellular compartment enriched in up-regulated proteins 
of MSCs-derived vesicles were extracellular region, plasma membrane, cell periphery, 
exosomes and vesicles (Figure.20). The top KEGG signaling pathways that are enriched 
in up-regulated proteins in MSCs-derived vesicles includes ECM-receptor interaction, 
cardiomyopathy, focal adhesion, Pl3K-Akt signaling pathway, and hematopoietic cell 
lineage (Figure.21).  
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Figure.17: Bar plot of the top 20 significant enrichment analysis based on GO 
biological process (GOBP) for up-regulated proteins in MVs (blue) and in exosomes 
(red).  
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Figure.18: Bar plot of the top 20 significant enrichment developmental terms based on 
GOBP for up-regulated proteins in MVs (blue) and in exosomes (red).  
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Figure.19: Bar plot of the top 10 significant enrichment immunity related terms based on 
GOBP for up-regulated proteins in MVs (blue) and in exosomes (red). 
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Figure.20: Bar plot of the top 20 significant enrichment analysis based on GO cellular 
compartment (GOCC) for up-regulated proteins in MVs (blue) and in exosomes (red).  
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Figure.21: Bar plot of the top 20 significant enrichment analysis based on KEGG 
pathways for up-regulated proteins in MVs (blue) and in exosomes (red). 
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6. DISCUSSION 
 
 
 
Mesenchymal stem cells (MSCs) have recently been clinically investigated as 
agents for regenerative and immunomodulation therapy in the treatment of a variety of 
related diseases. A number of studies that investigated the underlying mechanisms 
suggested that therapeutic effects are mediated by the paracrine communication between 
MSCs and their target cells. It is thus necessary to deeply study these paracrine factors 
including extracellular vesicles (EVs) to elucidate their involvement in the therapeutic 
activity. 
 
Studying the proteome of MSCs-derived EVs will help understanding their roles 
and contributions to the therapeutic effects to treat diseases. Exploring the expression 
profiles of vesicles, and compare them to their donor cells (MSCs) should suggest novel 
protein candidates that could contribute to improve or establish new models of free cell 
based therapy. Such proteinaceous factors may, for example, play an important role in 
damaged tissue recovery. In our current quantitative proteomic analysis, we carried out 
triple dimethyl labeling LC-MS/MS based analysis, which facilitated detecting 
differentially expressed proteins between 3 labeled experimental groups: MSCs, 
microvesicles (MVs), and exosomes.  
 
Recently, Eirin and his colleagues analyzed the proteome of adipose MSCs-
derived EVs in general without separation (Eirin et al., 2016). They fractionated and 
digested MSCs and EVs protein in 6 fractions by in gel digest. Differential protein 
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expression was determined using a label free approach.  In our study, we go beyond that 
work by separating two MSCs-derived vesicle types: MVs isolated by 20,000 x g 
centrifugation and exosomes isolated by 100,000 x g centrifugation. Examining each type 
of vesicles separately allows for deeper proteomic analysis and offers the opportunity to 
start evaluating functional differences between the studied populations.   
 
The majority of proteins identified in our study (4986 out of total 5207 proteins) 
were commonly detected in all the experimental groups: MSCs, MVs, and exosomes. 
Very few proteins were detected exclusively in one group or in two groups only. 
Regardless of the intensity or differentially expression of these common proteins in each 
group, this supports the close proteome relationship in the three experimental samples 
and is explained by the process of vesicle biogenesis from the original cell, resulting in 
new membranous vesicles carrying components of the parental cell and parts of its 
plasma membrane.  
 
6.1. Correlation Between MSCs-derived EVs and Their Donor Cell 
As previously reported, the secreted vesicles carry most of the donor cell 
characteristics and components including the protein signatures. MSCs expressed on their 
surface CD73, CD90, and CD105. As expected, we also identified these MSC protein 
markers in our MSCs-derived MVs and exosomes. We found significantly enriched in 
vesicles the most common MSC classical surface markers such as NT5E (CD73: 7 fold in 
MVs and 6.5 fold in EXO), THY1 (CD90: 4.5 fold in MVs and 6 fold in EXO), and 
ENG/ endoglin (CD105: 6 fold in MVs and 5 fold in EXO). Other MSC associated 
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proteins have been quantified as well, such as CD44 (6 fold in MVs and 5 fold in EXO), 
ALCAM (CD166: 3.5 fold in MVs and 1.5 fold in EXO), Integrin beta-1 (CD29: 4 fold 
in MVs and in EXO), endosialin (CD248: 10.5 fold in MVs and 5 fold in EXO), and 
CD276 (4.5 fold in MVs and 4 fold in EXO). Theses findings demonstrate that MSCs-
derived EVs do not only share the original cell proteome contents, but also are enriched 
for a subset of markers considered MSC-specific. This fact may lend credibility to the 
hypothesis that MSC vesicular secretions may indeed be a valuable replacement for the 
cells itself in cell-free applications. 
 
6.2. Involvement of MSCs-derived EVs in Therapeutic Applications 
A recent study found that MSCs could promote pro-coagulation process which 
decrease the myocardial infraction size (Gleeson et al., 2015). Consistent with this 
finding, we observed remarkable expression of proteins in both MVs and exosomes that 
are involved in blood coagulation and hemostasis including antithrombin-III 
(SERPINC1), fibronectin (FN1), integrin beta-3 (ITGB3), low-density lipoprotein 
receptor-related protein 8 (LRP8), neurobeachin-like protein 2 (NBEAL2). 
 
Lactadherin (MFGE8), was previously known to be involved in the phagocytic 
removal of apoptotic cells and improve mucosal healing in many cells (Raymond et al., 
2009) . In our study, we detected MFGE8 significantly with high fold increase in MVs. 
As a recent clinical trial (trial registration no. NCT01221428) concluded that MSCs 
infusion in a damaged colonic mucosa might be useful and repair ulcerative colitis (Hu et 
al., 2016)., MSC-derived EVs may thus. 
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MSCs directly or via vesicles recruit needed cells in common tissue homeostasis 
as well as toward sites of injury. They stimulate migration of endothelial or vascular 
smooth muscle cells, and reduce tissue damage (Liang et al., 2014; Li et al., 2016). In 
accordance with that work, we observed a significant enrichment of proteins that are 
associated with motility, migration and adhesion terms. Proteins such as coronin 
(CORO1A), protocadherin Fat-1 (FAT1), endoglin (ENG), CD44, and integrin alpha 
group (ITGA) etc. were significantly up-regulated in MVs and exosomes. Moreover, 
some of these proteins such as fibronectin (FN1), integrin beta-3 (ITGB3), laminin 
subunit alpha-4 (LAMA4), low-density lipoprotein receptor-related protein 8 (LRP8) etc. 
were highly enriched in MVs and exosomes when compared to MSCs. Enrichment of 
these proteins indicates that EVs induce cell migration to the sites of injury, attachment to 
target cells, and subsequently initiating the process of tissue repairing.  
 
Up-regulation of proteins that enhance tissue development processes were 
observed in the enrichment analysis of vesicles compared to their donor cell (MSCs). As 
expected, GOBP enrichment analysis confirms the high expression of MV and exosome 
proteins that are involved in therapeutic effects of MSCs including tissue regeneration 
and immune-modulation. More specifically, tissue specific proteins that are involved in 
angiogenesis, nervous system, heart, renal, retina, cartilage, muscles, and many other 
tissues were found enriched in EVs. These data may correlate with the large field of 
therapeutic applications of MSCs, as they are participating in tissue repair by modulating 
different cellular cascades in the recipient cells.  
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6.3. Differences Between Microvesicles and Exosomes  
Similar GOBP, GOCC, and KEGG terms were found enriched in both MVs and 
exosomes with minor differences in significance values and hint at close potential 
functional concordance despite the size difference. 
 
A small number of proteins show different significance and enrichment between 
MVs and exosomes when compared to MSCs. Peroxidasin homolog (PXDN), Collagen 
alpha-3 (VI) chain (COL6A3), Latent transforming growth factor beta-binding protein-2 
(LTBP2), apolipoprotein B-100 (APOB), and pentraxin-related protein (PTX3) are some 
selected proteins from the top 36 significantly up-regulated exosome proteins that 
showed more up-regulation in exosomes compared to MVs. Interestingly, PXDN, 
COL6A3, and LTBP2 were found to be involved in extracellular matrix generation 
process, a preliminary sign for the subsequent stages in tissue repairing. 
 
Despite the overall similarity, these findings may reflect minor specialization and 
complementarity of MVs and exosomes to each other. Those slight differences between 
the proteomes of each vesicles type should be considered when choosing harvesting 
methods for potential clinical applications to potentially include all vesicle types and 
preserve the largest effect potential possible. 
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7. CONCLUSION 
 
 
 
In conclusion, this quantitative proteomic study provides a reference set of MSCs-
derived EV proteins and their enrichment as compared to the parental cell. It contributes 
to our understanding of the potential role of EVs in free cell therapy. Therefore, this 
study may provide a guide for future studies aiming at replacing MSC in clinical 
applications. Further work on proteins excluded from secreted vesicles will deepen that 
understanding and provide more ground for optimization. Ultimately, in vivo studies with 
MSCs-derived EVs, their subpopulation and finally artificial vesicles reconstituted with 
candidate effector proteins are needed to confirm these data and elucidate how close our 
in vitro findings match the clinical situation and can contribute to cell-free therapies.     
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